Trials / Unknown
UnknownNCT05480501
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
- Status
- Unknown
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 9 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 3 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label to assess the efficacy and safety of IM19 CAR-T cells in R/R B-cell Acute Lymphoblastic Leukemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IM19 CAR-T cells | IM19 CAR-T cells administrated in a dosage to be selected by physician from a specific range. |
Timeline
- Start date
- 2022-07-11
- Primary completion
- 2024-08-01
- Completion
- 2024-10-01
- First posted
- 2022-07-29
- Last updated
- 2022-07-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05480501. Inclusion in this directory is not an endorsement.